Clinical evaluation of leukocyte filtration as an alternative anti-inflammatory strategy to aprotinin in high-risk patients undergoing coronary revascularization
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The use of aprotinin in cardiac surgery is associated with overriding safety concerns. Therefore, there is increased research on alternatives. This study investigated the relative benefits of strategic leukofiltration on polymer-coated extracorporeal circuits (ECC), aprotinin, and combined therapy in high-risk patients.
Eight hundred and seventy-five patients (EuroSCORE 6+) undergoing coronary revascularization over a 4-year period were prospectively randomized to one of four perfusion protocols: Group 1: polymethoxyethylacrylate (PMEA)-coated circuits + leukocyte filters (n = 214); Group 2: uncoated ECC + full Hammersmith aprotinin (n = 212); Group 3: PMEA-coated ECC + leukofilters + full Hammersmith aprotinin (n = 199); and Group 4: control—no treatment (n = 250). Blood samples were collected at times T1: following the induction of anesthesia; T2: following heparin administration; T3: 15 min after cardiopulmonary bypass (CPB); T4: before cessation of CPB; T5: 15 min after protamine reversal; and T6: in the intensive care unit.
The serum interleukin-2 levels were significantly lower at T3, T4, and T5 in all study groups. C3a levels were significantly lower at T3. Creatine kinase MB and lactate levels demonstrated well-preserved myocardia in both leukofiltration groups (P < 0.05). Neutrophil CD11b/CD18 levels were significantly lower for all study groups. Postoperative bleeding and respiratory support time were lower in all study groups.
Leukofiltration on coated circuits significantly reduced bleeding and inflammatory response related to CPB with no adverse effects, and may be a possible alternative to pharmacological intervention.
- Kozik DJ, Tweddell JS. Characterizing the inflammatory response to cardiopulmonary bypass in children. Ann Thorac Surg. 2006;81:2347–54. CrossRef
- Ortolano GA, Aldea GS, Lilly K, O’Gara P, Alkon JD, Mader F, et al. A review of leukofiltration in cardiac surgery: the time course of reperfusion injury may facilitate study design of anti-inflammatory effects. Perfusion. 2002;17:S53–62. CrossRef
- Matheis G, Scholz M, Simon A, Henrich D, Wimmer-Greinecker G, Moritz A. Timing of leukocyte filtration during cardiopulmonary bypass. Perfusion. 2001;16:S31–7. CrossRef
- Bechtel JF, Mühlenbein S, Eichler W, Marx M, Sievers HH. Leukocyte depletion during cardiopulmonary bypass in routine adult cardiac surgery. Interact Cardiovasc Thorac Surg. 2011;12(2):207–12. CrossRef
- Lindvall G, Sartipy U, Linden J. Aprotinin reduces bleeding and blood product use in patients treated with clopidogrel before coronary artery bypass grafting. Ann Thorac Surg. 2005;80:922–7. CrossRef
- Sodha NR, Boodhwani M, Bianchi C, Ramlawi B, Sellke FW. Aprotinin in cardiac surgery. Expert Rev Cardiovascular Ther. 2006;4(2):151–60. CrossRef
- Poston RS, White C, Gu J, Brown J, Gammie J, Pierson RN, et al. Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting. Ann Thorac Surg. 2006;81:104–11. CrossRef
- Mangano DT, Tudor IC, Dietzel C. Risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354(4):353–65. CrossRef
- Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999;16:9–13. CrossRef
- Repo H, Jansson SE, Leirisalo-Repo M. Flow cytometric determination of CD11b upregulation in vivo. J Immunol Methods. 1993;164:193–202. CrossRef
- Gourlay T, Connolly P. Does cardiopulmonary bypass still represent a good investment? The biomaterials perspective. Perfusion. 2003;18(4):225–31. CrossRef
- Boodram S, Evans E. Use of leukocyte-depleting filters during cardiac surgery with cardiopulmonary bypass: a review. J Extra Corpor Technol. 2008;40(1):27–42.
- Beierlein W, Scheule AM, Dietrich W, Ziemer G. Forty years of clinical aprotinin use: a review of 124 hypersensitivity reactions. Ann Thorac Surg. 2005;79:741–8. CrossRef
- Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg. 2004;128:442–8. CrossRef
- Fauli A, Gomar C, Campistol JM, Alvarez L, Manig AM, Matute P. Kidney-specific proteins in patients receiving aprotinin at high- and low-dose regimens during coronary artery bypass graft with cardiopulmonary bypass. Eur J Anaesthesiol. 2005;22:666–71. CrossRef
- Royston D. Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery? Ann Thorac Surg. 2006;82(4):1575. CrossRef
- Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358(22):2319–31. CrossRef
- Brown JR, Toler AW, Kramer RS, Landis RC. Anti-inflammatory effect of aprotinin: a meta-analysis. J Extra Corpor Technol. 2009;41(2):79–86.
- Gunaydin S, Sari T, McCusker K, Vijay V, Aydin H, Farsak B, et al. Clinical evaluation strategic leukofiltration with surface modification: enhanced preservation or fantasy. Filtration. 2005;1(1):57–67.
- Gunaydin S, McCusker K, Vijay V, Sari T, Sargon MF, Onur MA, et al. Clinical significance of strategic leukocyte filtration in different risk cohorts undergoing cardiac surgery. Filtration. 2005;1(2):95–106.
- Gunaydin S, Modine T, Sari T, Zorlutuna Y, Gourlay T. Clinical efficacy of two-phase leukocyte filtration in high-risk patients undergoing coronary revascularization with cardiopulmonary bypass. J Extra Corpor Technol. 2009;41(3):149–56.
- Gunaydin S, McCusker K, Vijay V. Strategic leukofiltration in cardiac surgery. Curr Med Chem. 2005;3:173–9.
- McCarthy PM, Yared JP, Foster RC, Ogella DA, Borsh JA, Cosgrove DM. A prospective randomized trial of Duraflo II heparin coated circuits in cardiac reoperations. Ann Thorac Surg. 1999;67:1268–73. CrossRef
- Ilmakunnas M, Pesonen EJ, Ahonen JA, Ramo J, Siitonen S, Repo H. Activation of neutrophils and monocytes by a leukocyte depleting filter used throughout cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2005;129:851–9. CrossRef
- Edmunds H, Colman RW. Thrombin during cardiopulmonary bypass. Ann Thorac Surg. 2006;82:2315–22. CrossRef
- Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Miyazaki M. Immunosuppression following surgical and traumatic injury. Surg Today. 2010;40(9):793–808. CrossRef
- Clinical evaluation of leukocyte filtration as an alternative anti-inflammatory strategy to aprotinin in high-risk patients undergoing coronary revascularization
Volume 42, Issue 4 , pp 334-341
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Cardiopulmonary bypass
- Leukocyte reduction procedure
- Industry Sectors
- Author Affiliations
- 1. Department of Cardiovascular Surgery, Bayindir Hospital, Sogutozu, 06530, Ankara, Turkey
- 2. Department of Cardiovascular Surgery, School of Medicine, University of Kirikkale, Fabrikalar mah, 71000, Kirikkale, Turkey